Protagonist Therapeutics(PTGX)
$124.67-0.16 (-0.13%)
PTGX
Protagonist Therapeutics financials statements
$124.67
At close:-0.16 (-0.13%)
Want to see PTGX full AI Analyst Report?
Protagonist Therapeutics (PTGX) Ratios
777 Followers
Protagonist Therapeutics Ratios
PTGX's free cash flow for Q3 2026 was $-23.46M. For the 2026 fiscal year, PTGX's free cash flow was decreased by $-237.00K and operating cash flow was $-23.22M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 |
| Quick Ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 |
| Cash Ratio | 2.83 | 2.05 | 8.78 | 4.03 | 2.81 |
| Solvency Ratio | -2.34 | 3.98 | -3.56 | -3.84 | -2.58 |
| Operating Cash Flow Ratio | 1.27 | 3.89 | -3.30 | -3.47 | -2.45 |
| Short-Term Operating Cash Flow Coverage | 25.26 | 361.08 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 522.39M | $ 522.21M | $ 334.30M | $ 210.76M | $ 293.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.00 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.10 | 1.06 | 1.15 | 1.16 |
| Debt Service Coverage Ratio | -56.45 | 541.20 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.16 | 0.18 | 0.02 | 0.07 | 0.13 |
| Net Debt to EBITDA | 0.92 | -0.31 | 2.05 | 0.95 | 0.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 97.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -281.01% | 64.32% | -156.09% | -494.24% | -460.01% |
| EBITDA Margin | -278.23% | 64.51% | -150.57% | -481.56% | -449.87% |
| Operating Profit Margin | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% |
| Pretax Profit Margin | -281.01% | 64.32% | -131.59% | -479.26% | -458.94% |
| Net Profit Margin | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% |
| Continuous Operations Profit Margin | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% |
| Net Income Per EBT | 100.65% | 98.49% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 81.78% | 110.51% | 84.31% | 96.97% | 99.77% |
| Return on Assets (ROA) | -19.43% | 36.95% | -22.06% | -51.38% | -36.11% |
| Return on Equity (ROE) | -21.17% | 40.75% | -23.45% | -59.09% | -41.85% |
| Return on Capital Employed (ROCE) | -25.32% | 36.26% | -27.82% | -60.61% | -41.44% |
| Return on Invested Capital (ROIC) | -25.23% | 35.69% | -27.72% | -59.92% | -41.14% |
| Return on Tangible Assets | -19.43% | 36.95% | -22.06% | -51.38% | -36.11% |
| Earnings Yield | -2.34% | 11.58% | -6.07% | -23.81% | -7.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.23 | 2.58 | 5.81 | 511.17 | 5.13 |
| Payables Turnover | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.94 | 34.46 | 27.92 | 5.75 | 4.06 |
| Asset Turnover | 0.07 | 0.58 | 0.17 | 0.11 | 0.08 |
| Working Capital Turnover Ratio | 0.09 | 0.99 | 0.22 | 0.10 | 0.10 |
| Cash Conversion Cycle | -1555.14 | 141.56 | 62.85 | 0.71 | 71.15 |
| Days of Sales Outstanding | 35.66 | 141.56 | 62.85 | 0.71 | 71.15 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1590.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 35.66 | 141.56 | 62.85 | 0.71 | 71.15 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.91 | 2.99 | -1.24 | -2.20 | -2.33 |
| Free Cash Flow Per Share | 0.88 | 2.97 | -1.25 | -2.22 | -2.35 |
| Dividend Paid and CapEx Coverage Ratio | 36.27 | 135.91 | -115.33 | -136.02 | -97.97 |
| Capital Expenditure Coverage Ratio | 36.27 | 135.91 | -115.33 | -136.02 | -97.97 |
| Operating Cash Flow Coverage Ratio | 5.59 | 16.95 | -61.56 | -29.58 | -18.41 |
| Operating Cash Flow to Sales Ratio | 1.25 | 0.42 | -1.17 | -4.07 | -3.94 |
| Free Cash Flow Yield | 1.01% | 7.69% | -5.44% | -20.36% | -6.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -42.60 | 8.64 | -16.49 | -4.20 | -12.62 |
| Price-to-Sales (P/S) Ratio | 120.66 | 5.47 | 21.69 | 20.13 | 57.91 |
| Price-to-Book (P/B) Ratio | 9.03 | 3.52 | 3.87 | 2.48 | 5.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 99.01 | 13.00 | -18.37 | -4.91 | -14.54 |
| Price-to-Operating Cash Flow Ratio | 96.28 | 12.91 | -18.53 | -4.95 | -14.69 |
| Price-to-Earnings Growth (PEG) Ratio | 0.29 | -0.02 | 0.37 | 0.86 | -0.33 |
| Enterprise Value Multiple | -42.45 | 8.17 | -12.35 | -3.23 | -11.92 |
| Enterprise Value | 5.43B | 2.29B | 1.12B | 412.96M | 1.47B |
| EV to EBITDA | -42.45 | 8.17 | -12.35 | -3.23 | -11.92 |
| EV to Sales | 118.10 | 5.27 | 18.60 | 15.54 | 53.60 |
| EV to Free Cash Flow | 96.90 | 12.53 | -15.75 | -3.79 | -13.46 |
| EV to Operating Cash Flow | 94.23 | 12.44 | -15.89 | -3.82 | -13.60 |
| Tangible Book Value Per Share | 9.67 | 10.97 | 5.93 | 4.40 | 6.48 |
| Shareholders’ Equity Per Share | 9.67 | 10.97 | 5.93 | 4.40 | 6.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.72 | 7.06 | 1.06 | 0.54 | 0.59 |
| Net Income Per Share | -2.05 | 4.47 | -1.39 | -2.60 | -2.71 |
| Tax Burden | 1.01 | 0.98 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.84 | 0.97 | 1.00 |
| Research & Development to Revenue | 3.46 | 0.32 | 2.00 | 4.75 | 4.61 |
| SG&A to Revenue | 0.97 | 0.10 | 0.56 | 1.19 | 0.99 |
| Stock-Based Compensation to Revenue | 1.00 | 0.09 | 0.49 | 0.91 | 0.60 |
| Income Quality | -0.44 | 0.67 | 0.89 | 0.85 | 0.86 |
Currency in USD

